Literature DB >> 19691089

Bayesian statistics in oncology: a guide for the clinical investigator.

Michel Adamina1, George Tomlinson, Ulrich Guller.   

Abstract

The rise of evidence-based medicine as well as important progress in statistical methods and computational power have led to a second birth of the >200-year-old Bayesian framework. The use of Bayesian techniques, in particular in the design and interpretation of clinical trials, offers several substantial advantages over the classical statistical approach. First, in contrast to classical statistics, Bayesian analysis allows a direct statement regarding the probability that a treatment was beneficial. Second, Bayesian statistics allow the researcher to incorporate any prior information in the analysis of the experimental results. Third, Bayesian methods can efficiently handle complex statistical models, which are suited for advanced clinical trial designs. Finally, Bayesian statistics encourage a thorough consideration and presentation of the assumptions underlying an analysis, which enables the reader to fully appraise the authors' conclusions. Both Bayesian and classical statistics have their respective strengths and limitations and should be viewed as being complementary to each other; we do not attempt to make a head-to-head comparison, as this is beyond the scope of the present review. Rather, the objective of the present article is to provide a nonmathematical, reader-friendly overview of the current practice of Bayesian statistics coupled with numerous intuitive examples from the field of oncology. It is hoped that this educational review will be a useful resource to the oncologist and result in a better understanding of the scope, strengths, and limitations of the Bayesian approach. (c) 2009 American Cancer Society.

Mesh:

Year:  2009        PMID: 19691089     DOI: 10.1002/cncr.24628

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design.

Authors:  Hallie C Prescott; Carolyn S Calfee; B Taylor Thompson; Derek C Angus; Vincent X Liu
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

2.  Outcome--adaptive randomization: is it useful?

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

3.  Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients.

Authors:  Aurélie Velay; Morgane Solis; Ilies Benotmane; Pierre Gantner; Eric Soulier; Bruno Moulin; Sophie Caillard; Samira Fafi-Kremer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  A probabilistic analysis of completely excised high-grade soft tissue sarcomas of the extremity: an application of a Bayesian belief network.

Authors:  Jonathan Agner Forsberg; John H Healey; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2012-04-20       Impact factor: 5.344

Review 5.  "Petite" p value: A Researchers' Dream! Readers, Beware of the Pit ….

Authors:  Sharada Mailankody; Jyoti Bajpai; Sudeep Gupta
Journal:  Indian J Crit Care Med       Date:  2020-04

6.  Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?

Authors:  Koichi Ogura; Tabu Gokita; Yusuke Shinoda; Hirotaka Kawano; Tatsuya Takagi; Keisuke Ae; Akira Kawai; Rikard Wedin; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2017-05-30       Impact factor: 4.176

7.  Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network.

Authors:  Jonathan Agner Forsberg; John Eberhardt; Patrick J Boland; Rikard Wedin; John H Healey
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

8.  Bayesian cohort and cross-sectional analyses of the PINCER trial: a pharmacist-led intervention to reduce medication errors in primary care.

Authors:  Karla Hemming; Peter J Chilton; Richard J Lilford; Anthony Avery; Aziz Sheikh
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

Review 9.  Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

Authors:  Eric J Bow; David J Vanness; Monica Slavin; Catherine Cordonnier; Oliver A Cornely; David I Marks; Antonio Pagliuca; Carlos Solano; Lael Cragin; Alissa J Shaul; Sonja Sorensen; Richard Chambers; Michal Kantecki; David Weinstein; Haran Schlamm
Journal:  BMC Infect Dis       Date:  2015-03-17       Impact factor: 3.090

10.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.